{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:24:23Z","timestamp":1765887863031,"version":"3.48.0"},"reference-count":12,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,2,2]]},"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Co-administration of a diuretic or calcium channel blocker with an ACE inhibitor are both preferred combinations in patients with hypertensive chronic kidney disease (CKD). According to the available evidence, it is still unknown which combination plays a more active role in renal protection. We hypothesised that a combination of fosinopril and benidipine may delay the progression of CKD more effectively than a combination of fosinopril and hydrochlorothiazide (HCTZ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This study will be a multicentred, prospective, double-blind, randomised parallel controlled trial for hypertensive CKD patients in China. Patients will be randomised to one of two treatment groups: a combination of benidipine 4\u20138\u2005mg\/day and fosinopril 20\u2005mg\/day; or a combination of HCTZ 12.5\u201325\u2005mg\/day and fosinopril 20\u2005mg\/day. Patients will be followed up for 24\u2005months after a month's fosinopril run-in. There will be dose-titration after 1 and 2\u2005months. The primary endpoint is changes in estimated glomerular filtration rate (eGFR) from baseline to month 24. Secondary endpoints include changes in home blood pressure (BP), ambulatory BP, proteinuria, urinary albumin\/creatinine ratio, and composite renal events in 24\u2005months. Inclusion criteria are: age 18\u201380\u2005years, non-dialysis CKD patients with eGFR &gt;30\u2005mL\/min\/1.73\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      , home BP &gt;130\u2005mm\u2005Hg systolic or BP &gt;80\u2005mm\u2005Hg diastolic at the screening and randomisation, and 24\u2005hour proteinuria &lt;3.5\u2005g. Principal exclusions are hypertensive crisis, transplantation, cancer, severe diabetes complications, hyperkalaemia and severe allergy. The required sample size was 511 patients for detecting a difference in the change of eGFR (one sided \u03b1=0.025, power 1-\u03b2=0.90).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>BEAHIT (Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients with Hypertension) was approved by Changzheng Hospital Ethics Committee (CZ-20160504-16). The outcomes will be published in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT02646397.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013672","type":"journal-article","created":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T20:10:15Z","timestamp":1488053415000},"page":"e013672","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02646397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02646397","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Cheng","family":"Xue","sequence":"first","affiliation":[{"name":"Division of Nephrology, Kidney Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China"},{"name":"Department of Pharmacy, 309 Hospital of PLA, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Kidney Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Lv","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Kidney Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Kidney Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengqiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Kidney Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanren","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, 309 Hospital of PLA, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlin","family":"Mei","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Kidney Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"key":"2025121511561334000_7.2.e013672.1","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1111\/j.1523-1755.2005.09416.x","article-title":"Prevention of the progression of chronic kidney disease: practice in China","volume":"94","author":"Wang","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"2025121511561334000_7.2.e013672.2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.425"},{"key":"2025121511561334000_7.2.e013672.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00912.x"},{"key":"2025121511561334000_7.2.e013672.4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.102"},{"key":"2025121511561334000_7.2.e013672.5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10157-015-1091-5","article-title":"Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study","volume":"19","author":"Hayashi","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"2025121511561334000_7.2.e013672.6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/10641963.2010.503299","article-title":"Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease","volume":"33","author":"Ishimitsu","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"2025121511561334000_7.2.e013672.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62100-0"},{"key":"2025121511561334000_7.2.e013672.8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/hr.2009.11","article-title":"Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3\u20135 chronic kidney disease","volume":"32","author":"Abe","year":"2009","journal-title":"Hypertens Res"},{"key":"2025121511561334000_7.2.e013672.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025121511561334000_7.2.e013672.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.03.018"},{"key":"2025121511561334000_7.2.e013672.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2025121511561334000_7.2.e013672.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6634"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:56:19Z","timestamp":1765828579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,24]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/bmjopen-2016-013672"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013672","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}